新股消息 | 泽璟制药递表港交所

Group 1 - The core point of the article is that Suzhou Zelgen Biopharmaceuticals Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CICC as the sole sponsor [1] - Zelgen Biopharmaceuticals is a comprehensive biopharmaceutical company focused on the discovery, research and commercialization of innovative small molecules and biological agents, with strategic focus on oncology, autoimmune diseases, and hemostasis/blood diseases [1] - The product portfolio includes three marketed drugs: Zepsu, the first domestically developed small molecule multi-target drug for first-line treatment of advanced liver cancer in China; Zepsin, the first innovative JAK inhibitor for treating myelofibrosis developed in China; and Zepsinogen, the only recombinant human thrombin developed and commercialized using recombinant DNA technology in China [1]